Swayampakula Ramakanth, an analyst from H.C. Wainwright, has initiated a new Hold rating on Aethlon Medical (AEMD).
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Swayampakula Ramakanth has given his Hold rating due to a combination of factors related to Aethlon Medical’s current position and future prospects. The company is developing the Hemopurifier, a device aimed at enhancing the efficacy of anti-PD-1 therapies by removing cancer-promoting exosomes. While the potential of this technology is promising, it is still in the early stages of clinical development, with a pivotal study not expected to be completed until the second half of 2026.
Despite the encouraging preclinical data, there are no significant catalysts anticipated in the next year, and the company faces financial challenges. The ongoing feasibility study in Australia is a step forward, but the results are not expected until later, which contributes to the cautious outlook. The Hold rating reflects the balance between the potential market opportunity and the current uncertainties, including the need for a development and commercial partner to advance the Hemopurifier’s progress.
Ramakanth covers the Healthcare sector, focusing on stocks such as Ocugen, ALX Oncology Holdings, and Unicycive Therapeutics. According to TipRanks, Ramakanth has an average return of 3.2% and a 38.00% success rate on recommended stocks.
In another report released on June 27, Maxim Group also maintained a Hold rating on the stock with a $5.00 price target.